Clinical trials: Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
RV6153 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02517359
- Testing
- RV6153 single dose, RV6153 14 day repeat dose, RV6153 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller…
- Trial name
- WAYFINDER (NCT05274815)
- Testing
- Tezepelumab
- Where
- 77 sites in United States, Argentina and 9 more
- Volunteers
- 305 people
- Sponsor
- AstraZeneca
Asthma
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.
- Trial name
- MITRA (NCT01433523)
- Testing
- ALK HDM AIT 6 DU, ALK HDM AIT 12 DU
- Where
- Germany
- Volunteers
- 834 people
- Sponsor
- ALK-Abelló A/S
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007).
- Trial name
- NCT01970878
- Testing
- GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005)
- Where
- 125 sites in United States, Australia and 1 more
- Volunteers
- 892 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)
This will be a randomized, double-blind, single-dose, three-period balanced crossover study in adult healthy subjects. Each of the 18 subjects will be randomized to receive a treatment sequence consisting of each of the three…
- Trial name
- NCT01725685
- Testing
- FF 400 mcg, UMEC 500 mcg, FF/UMEC 400/500 mcg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Asthma
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
The purpose of this study was to evaluate whether 2 puffs of fixed combination of aerosolized 120 mcg salbutamol sulphate (equivalent to 100 mcg of the base) + 20 mcg ipratropium bromide confers significant additional protection…
- Trial name
- NCT02182713
- Testing
- Salbutamol sulfate/Ipratropium bromide, Salbutamol
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.
- Trial name
- PASSION (NCT00628758)
- Testing
- Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Cardiac Safety of Indacaterol
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
- Trial name
- NCT01263808
- Testing
- Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg
- Where
- United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Asthma
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Montelukast Tablet under fed conditions
- Trial name
- NCT01659918
- Testing
- Montelukast, Singulair
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Asthma
Self-Management Of Asthma By Forced Oscillation Technique
Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing and responding to deterioration in control with effective treatments can improve asthma…
- Trial name
- PIANOFORTE (NCT04963140)
- Testing
- Optimized self-management of asthma, Conventional self-management of asthma
- Where
- 9 sites in Australia, France and 1 more
- Volunteers
- 39 people
- Sponsor
- Restech Srl
Chronic Obstructive Pulmonary Disease
Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in the treatment of cough in patients with stable obstructive pulmonary disease
- Trial name
- NCT03159091
- Testing
- Rengalin
- Where
- 18 sites in Russia
- Volunteers
- 238 people
- Sponsor
- Materia Medica Holding
Asthma
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
A randomized multiple-dose, placebo-controlled, parallel group design consisting of a 2-week run-in period followed by a 6-week treatment period of the placebo, Test product (Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5…
- Trial name
- NCT03015259
- Testing
- Budesonide/Formoterol fumarate dihydrate, Symbicort
- Where
- 95 sites in United States
- Volunteers
- 1,762 people
- Sponsor
- Kindeva Drug Delivery
Pulmonary Disease, Chronic Obstructive
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431287
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 240 sites in United States, Austria and 22 more
- Volunteers
- 2,539 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD…
- Trial name
- NCT05567406
- Testing
- Belumosudil
- Sponsor
- Kadmon, a Sanofi Company
Asthma
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug delivery characteristics comparable to the…
- Trial name
- NCT01540708
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.
- Trial name
- NCT00557440
- Testing
- fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate
- Where
- 6 sites in Belgium, Germany
- Volunteers
- 37 people
- Sponsor
- Novartis